Johnson & Johnson (JNJ -0.71%) reported first-quarter 2018 results this week that outpaced industry watchers' forecasts. Its $20 billion in quarterly revenue clocked in over $600 million higher than expected and its adjusted earnings per share of $2.06 beat analysts by $0.05. There were a lot of contributors to the company's outperformance last quarter, but sales growth for Darzalex, Stelara, and Zytiga provided the biggest tailwinds.
First, the numbers
J&J generates billions of dollars in annual sales from selling consumer goods, such as Band-Aid products, and medical devices used in surgeries, but it's the company's pharmaceuticals business that determines whether the company's results are better or worse than anticipated.
During the first quarter, pharmaceutical sales accounted for $9.8 billion, or 49%, of the company's revenue. For comparison, consumer goods and medical devices contributed $3.4 billion and $6.8 billion, respectively.
Overall, J&J's drug revenue increased by 19.4%, but a big chunk of that increase came from drugs acquired when it bought Actelion and currency exchange tailwinds. If you back out currency impacts, year-over-year drug revenue growth drops to 15.1% in the quarter, and if you remove the sales associated with Actelion's drugs, then J&J's biopharma sales growth falls to a much tamer 4.3%.
Three big drivers of growth
J&J's fastest growing drugs did a lot of heavy-lifting last quarter, and as a result drug revenue was able to increase despite biosimilar competition to its best-selling drug Remicade. Remicade is a widely used autoimmune disease drug, and until recently it accounted for more than 15% of J&J's pharmaceutical revenue.
But the drug's contribution to J&J's financials is decreasing following the entrance of biosimilars, including Pfizer's (PFE -0.91%) Inflectra. Last quarter, competing on price to maintain its market share caused Remicade's sales to slip 18% to $1.4 billion after adjusting for currency conversion. As a result, it only represented 14.3% of J&J's pharmaceutical sales.
The $283 million headwind to revenue caused by declining prices for Remicade was more than made up, though, by growing demand for by its multiple myeloma drug, Darzalex, its autoimmune disease drug, Stelara, and its prostate cancer drug, Zytiga.
Darzalex's sales skyrocketed 69.4% year over year, or by $177 million, to $432 million in the quarter. The reason for the growth in the past year is twofold. First, Darzalex is becoming a more widely used drug globally. As of March 31, it's available in 29 countries, including Japan, where it secured approval last November. Second, Darzalex secured an important FDA label expansion last year for its use as a second-line multiple myeloma treatment rather than only as a third-line therapy. In Q1, it secured 24% of new-to-brand market share in the second-line setting.
Initially approved in 2009 for psoriasis, Stelara's been around a lot longer than Darzalex, but like Darzalex, its sales are benefiting from a label expansion. In 2016, it won an FDA go-ahead for use in Crohn's disease and its sales have been accelerating ever since. Stelara's sales increased 24.1%, ex-currency, to $1.06 billion in Q1. That growth contributed an extra $238 million to J&J's top line compared to Q1 2017.
Zytiga wasn't a slouch, either. Sales of the prostate cancer drug jumped 61.6% to $845 million in Q1 following a label expansion in February that allows its use for patients with metastatic high-risk castration sensitive prostate cancer. Zytiga's approval was based on trials showing a 38% reduction in the risk of death in this subset of patients, an improvement that's clearly influencing doctor's use of the drug.
Can this growth continue?
Zytiga's future is murkier than the other two drugs because Zytiga's patent protection is expiring later this year and that may lead to the launch of generic drugs that begin to chip away at its market share. The company told investors on its Q1 conference call, however, that it doesn't anticipate any generic Zytiga launches this year, and as a result it expects Zytiga's revenue tailwinds to continue supporting its full-year revenue outlook for between $79.5 billion to $80.3 billion, which would be up 4% to 5% from 2017 on an ex-currency basis.
Stelara's U.S. patent doesn't expire until 2023, so it has a few more years to continue establishing itself in the Crohn's market. That market, however, could become more challenging if competing drugs, including Celgene's ozanimod, shine in late-stage studies. As a result, investors will want to keep an eye on progress being made by J&J's peers.
Finally, it seems that Darzalex's future may be the brightest of the three. So far, its trials have shown it can improve outcomes when used alongside other multiple myeloma drugs and that could offer it some insulation if the market gets disrupted by new treatment approaches, such as gene therapy.
Importantly, Darzalex's sales could get a significant boost if it wins FDA approval for use in the first-line setting. In December, management unveiled impressive first-line data from trials evaluating its use alongside Velcade and an FDA green light could be granted for first-line use within a few months. If so, then I think Darzalex could see another meaningful spike in its sales and it could be destined to be J&J's next big blockbuster.
Overall, J&J's got some challenges ahead of it because of expiring patents, but it's successfully using pricing to maintain market share. As long as that strategy continues to control the decline in Remicade's sales, then growth from these drugs should offset any drop -- at least until J&J has to deal with a generic Zytiga.